Raymond Debbane Purchases 100,000 Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Raymond Debbane bought 100,000 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was bought at an average cost of $1.47 per share, for a total transaction of $147,000.00. Following the transaction, the director directly owned 1,904,186 shares of the company’s stock, valued at $2,799,153.42. The trade was a 5.54% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Raymond Debbane also recently made the following trade(s):

• On Friday, February 20th, Raymond Debbane purchased 100,000 shares of Lexicon Pharmaceuticals stock. The shares were bought at an average price of $1.48 per share, with a total value of $148,000.00.
• On Thursday, February 19th, Raymond Debbane acquired 50,000 shares of Lexicon Pharmaceuticals stock. The stock was bought at an average price of $1.44 per share, for a total transaction of $72,000.00.

Lexicon Pharmaceuticals Stock Up 3.7%

Lexicon Pharmaceuticals stock opened at $1.54 on Wednesday. The company has a market capitalization of $557.93 million, a PE ratio of -8.08 and a beta of 0.98. The company has a debt-to-equity ratio of 0.47, a quick ratio of 5.63 and a current ratio of 5.64. Lexicon Pharmaceuticals, Inc. has a fifty-two week low of $0.28 and a fifty-two week high of $1.83. The firm has a 50 day moving average price of $1.30 and a 200 day moving average price of $1.31.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, January 22nd. Wall Street Zen cut shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Lexicon Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $3.23.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Security National Bank of Sioux City Iowa IA purchased a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter worth $31,000. Hudson Bay Capital Management LP purchased a new position in Lexicon Pharmaceuticals in the second quarter valued at $26,000. Leonteq Securities AG acquired a new stake in Lexicon Pharmaceuticals in the fourth quarter valued at $34,000. Vermillion & White Wealth Management Group LLC lifted its holdings in Lexicon Pharmaceuticals by 400.0% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 32,500 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 26,000 shares during the last quarter. Finally, EntryPoint Capital LLC acquired a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter worth about $39,000. Institutional investors and hedge funds own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.